Atlanta, GA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM), a leading provider of solutions that enable healthcare providers to improve financial performance, announced that it has expanded its agreement with a five hospital, Epic-EHR based health system in Pennsylvania. The system will add eValuator’s Pro-Fee pre-bill coding analysis technology to improve revenue integrity and financial performance for their professional fee services.
eValuator’s pre-bill code audit technology makes it easy for providers to identify, quantify and expedite correction of coding issues with the highest impact on revenue integrity. With eValuator, providers can optimize financial performance from their inpatient, outpatient, and professional-fee encounters through one platform, without billing delays.
“We are pleased to expand our relationship with this health system and to enable them to audit all of their records, prior to billing, across their continuum of care,” stated Ben Stilwill, Chief Executive Officer. “This expansion is a testament to the value of eValuator and to the strong relationships our Client Success team is building.”
About Streamline Health
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit www.streamlinehealth.net
To Learn More
Jacob Goldberger
Director, Investor Relations and FP&A
303.887.9625
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.18 |
| Daily Change: | -0.02 -0.38 |
| Daily Volume: | 26,499 |
| Market Cap: | US$22.120M |
May 01, 2025 January 22, 2025 December 18, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
